Agonist

Cells listen for signals through receptors, and an agonist is anything that lands on a receptor and gets it working. It doesn’t just sit there — it flips the receptor into its active state, so the cell behaves as if its natural messenger had shown up.

Think of a receptor as a lock and the agonist as a key that both fits and turns. A key that fits but won’t turn is a different thing entirely (that’s an antagonist). An agonist turns.

This is why the word shows up constantly in peptide research. A “GLP-1 receptor agonist” like semaglutide works by mimicking the gut hormone GLP-1 and switching on the same receptor, so the body responds as though it made more of the real hormone. A “melanocortin receptor agonist” flips the receptors tied to skin pigment and libido.

Take semaglutide as a concrete example. It selectively binds to and activates the GLP-1 receptor, satisfying both parts of the definition: binding gets the molecule to the receptor, while activation starts a response inside the cell. In the pancreas, that response increases insulin secretion and lowers glucagon when blood glucose is high; these are downstream effects, not just evidence that semaglutide touched the receptor. By contrast, if the same molecule fit the GLP-1 receptor but kept native GLP-1 from switching it on, it would behave as an antagonist instead; binding data alone therefore do not settle the label, because researchers must also see a clear, receptor-driven response to know that the key turned and then measure what that activation changes in the body.

When you see a peptide described as an agonist, read it as: this molecule presses the button. How hard it presses varies — a full agonist gives the maximum response, a partial agonist gives a weaker one even at full dose.